235 related articles for article (PubMed ID: 35353428)
1. BRAF V600E and previously unidentified KRAS G12C mutations in odontogenic tumors may affect MAPK activation differently depending on tumor type.
Oh KY; Kim JH; Cho SD; Yoon HJ; Lee JI; Hong SD
Genes Chromosomes Cancer; 2022 Aug; 61(8):481-490. PubMed ID: 35353428
[TBL] [Abstract][Full Text] [Related]
2. Adenoid ameloblastoma with dentinoid is molecularly different from ameloblastomas and adenomatoid odontogenic tumors.
Coura BP; Dos Santos JN; Fonseca FP; Bernardes VF; de Aquino SN; Jorge Júnior J; Vargas PA; Romañach MJ; de Andrade BAB; Gomez RS; Gomes CC
J Oral Pathol Med; 2021 Nov; 50(10):1067-1071. PubMed ID: 34549835
[TBL] [Abstract][Full Text] [Related]
3. The molecular basis of odontogenic cysts and tumours.
Gomes IP; Bastos VC; Guimarães LM; Gomes CC
J Oral Pathol Med; 2023 Apr; 52(4):351-356. PubMed ID: 36629457
[TBL] [Abstract][Full Text] [Related]
4. BRAF p.V600E mutations are not unique to ameloblastoma and are shared by other odontogenic tumors with ameloblastic morphology.
Brunner P; Bihl M; Jundt G; Baumhoer D; Hoeller S
Oral Oncol; 2015 Oct; 51(10):e77-8. PubMed ID: 26306423
[No Abstract] [Full Text] [Related]
5. Genetic Study of
Kokubun K; Yamamoto K; Akashi Y; Chujo T; Nakajima K; Matsuzaka K
Int J Surg Pathol; 2022 Jun; 30(4):378-384. PubMed ID: 34994576
[No Abstract] [Full Text] [Related]
6. Activating FGFR2-RAS-BRAF mutations in ameloblastoma.
Brown NA; Rolland D; McHugh JB; Weigelin HC; Zhao L; Lim MS; Elenitoba-Johnson KS; Betz BL
Clin Cancer Res; 2014 Nov; 20(21):5517-26. PubMed ID: 24993163
[TBL] [Abstract][Full Text] [Related]
7. Discrepancy between immunohistochemistry and sequencing for BRAF V600E in odontogenic tumours: Comparative analysis of two VE1 antibodies.
Oh KY; Cho SD; Yoon HJ; Lee JI; Hong SD
J Oral Pathol Med; 2021 Jan; 50(1):85-91. PubMed ID: 32939809
[TBL] [Abstract][Full Text] [Related]
8. The BRAF p.V600E mutation is a common event in ameloblastomas but is absent in odontogenic keratocysts.
Zhang R; Yang Q; Qu J; Hong Y; Liu P; Li T
Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Mar; 129(3):229-235. PubMed ID: 31987674
[TBL] [Abstract][Full Text] [Related]
9. Detection of MAPK/ERK pathway proteins and KRAS mutations in adenomatoid odontogenic tumors.
Bologna-Molina R; Ogawa I; Mosqueda-Taylor A; Takata T; Sánchez-Romero C; Villarroel-Dorrego M; Takeda Y; Mikami T
Oral Dis; 2019 Mar; 25(2):481-487. PubMed ID: 30294831
[TBL] [Abstract][Full Text] [Related]
10. [BRAF V600E expression in ameloblastomas, ameloblastic carcinomas and cysts].
Pei J; Zhang L; Jia YX; Chen WH
Shanghai Kou Qiang Yi Xue; 2023 Dec; 32(6):630-634. PubMed ID: 38494972
[TBL] [Abstract][Full Text] [Related]
11. Identification of BRAF V600E mutation in odontogenic tumors by high-performance MALDI-TOF analysis.
Togni L; Zizzi A; Mazzucchelli R; Santarelli A; Rubini C; Mascitti M
Int J Oral Sci; 2022 Apr; 14(1):22. PubMed ID: 35468886
[TBL] [Abstract][Full Text] [Related]
12. Ameloblastic fibrosarcoma: clinicopathological and molecular analysis of seven cases highlighting frequent BRAF and occasional NRAS mutations.
Agaimy A; Skalova A; Franchi A; Alshagroud R; Gill AJ; Stoehr R; Baumhoer D; Bauer S
Histopathology; 2020 May; 76(6):814-821. PubMed ID: 31899815
[TBL] [Abstract][Full Text] [Related]
13. Assessing pathogenic mutations in dental follicles as an attempt to identify early events in odontogenic tumours tumourigenesis.
Coura BP; de Resende TAC; de Menezes VCB; Bernardes VF; de Sousa SF; Diniz MG; Gomez RS; Gomes CC
Arch Oral Biol; 2020 May; 113():104523. PubMed ID: 31543246
[TBL] [Abstract][Full Text] [Related]
14. Molecular diagnostics in odontogenic tumors.
Buettner R; Gültekin SE
Pathologie (Heidelb); 2022 Aug; 43(Suppl 1):81-85. PubMed ID: 36378285
[TBL] [Abstract][Full Text] [Related]
15. Adenoid Ameloblastoma with BRAF p.V600E Mutation Revealing Ameloblastomatous Origin: A First Case Report.
Noda Y; Sawada S; Sakagami T; Kojima Y; Higasa K; Tsuta K
Head Neck Pathol; 2023 Sep; 17(3):788-792. PubMed ID: 37093491
[TBL] [Abstract][Full Text] [Related]
16. Detection and evaluation of the presence of the BRAF V600E mutation in ameloblastomas in an Indian population.
Goes CF; Spadigam A; Dhupar A; Carvalho KM; Cota J; Syed S
Indian J Pathol Microbiol; 2023; 66(2):246-251. PubMed ID: 37077063
[TBL] [Abstract][Full Text] [Related]
17. The Molecular Pathology of Odontogenic Tumors: Expanding the Spectrum of MAPK Pathway Driven Tumors.
Guimarães LM; Coura BP; Gomez RS; Gomes CC
Front Oral Health; 2021; 2():740788. PubMed ID: 35048058
[TBL] [Abstract][Full Text] [Related]
18. The diagnostic utility of BRAF VE1 mutation-specific immunohistochemistry in ameloblastoma.
Mendez LD; Wolsefer NS; Asa SL; Wasman J; Yoest JM; Stojanov IJ
Mod Pathol; 2022 Nov; 35(11):1570-1577. PubMed ID: 35676332
[TBL] [Abstract][Full Text] [Related]
19. Association of MDM2 Overexpression in Ameloblastomas with
Tosios KI; Kalogirou EM; Koutlas IG
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396916
[TBL] [Abstract][Full Text] [Related]
20. The Mutational Profile of Unicystic Ameloblastoma.
Heikinheimo K; Huhtala JM; Thiel A; Kurppa KJ; Heikinheimo H; Kovac M; Kragelund C; Warfvinge G; Dawson H; Elenius K; Ristimäki A; Baumhoer D; Morgan PR
J Dent Res; 2019 Jan; 98(1):54-60. PubMed ID: 30216733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
